Gelonghui, April 30 | Fu'an Pharmaceutical (300194.SZ) announced that Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. (“Qingyutang”), a wholly-owned subsidiary of the company, recently received a drug registration certificate issued by the State Drug Administration. The related drugs are pentazocin injection and midazolam injection, respectively.
Pentazocine injection is suitable for all kinds of severe chronic pain, such as cancerous pain, traumatic pain, and pain after surgery. It can also be used for administration before surgery or before anesthesia, as an adjuvant to surgical anesthesia. Up to now, 2 companies (including Qingyutang) have passed the consistency evaluation or deemed to have passed the consistency evaluation.
Midazolam injection indications are: 1. Intramuscular or intravenous administration for sedation/anxiety/memory loss before surgery. 2. Intravenous injections are used for sedation/anxiety/memory loss before or during operation during diagnosis, treatment, and endoscopic surgery (such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, tumor surgery, radiation procedures, tear stitches, and other processes used alone or in combination with other central nervous system inhibitors). 3. Intravenous injections are used to induce general anesthesia before administration of other anesthetics. In the case of the use of narcotic precursors, anesthesia induction can be achieved in a relatively narrow dosage range and in a short time. Intravenous midazolam can also be used as an intravenous supplement of nitrous oxide and oxygen (combined anesthesia). 4. Continuous intravenous infusion of midazolam is used as an anesthetic for sedation of patients with endotracheal intubation and mechanical ventilation, or for sedation in critical care and treatment. Up to now, 4 companies (including Qingyutang) have passed or deemed to have passed the consistency evaluation for this product.